IMAB News & Events

NovaBridge Biosciences has changed its corporate name from I-Mab to NovaBridge Biosciences. The change was overwhelmingly approved by shareholders at the Company's Extraordinary General Meeting held on October 24, 2025, and by the Company's Board of Directors. The Company's American Depositary Shares will trade on Nasdaq under the new name and a new ticker symbol, "NBP", effective at the opening of trading on October 30, 2025, replacing its current symbol "IMAB"/ The new corporate brand, including a new website, marks an important step in the Company's strategic transformation to a global biotechnology platform company committed to accelerating access to innovative medicines for patients worldwide. In connection with the name change and ticker symbol change, no action is required from current shareholders and the Company's CUSIP number will remain the same. Historical trading data of the Company's ADSs prior to October 30, 2025 may not yet be available on certain third-party websites and apps when searching for "NovaBridge Biosciences" and/or "NBP", in which case such data may temporarily be found under "I-MAB" and/or "IMAB". The Company intends to partner with leading innovators to identify and accelerate high-value assets. Our model integrates rigorous asset selection, bespoke translational strategies, and efficient clinical execution. With the backing of CBC Group, we leverage deep local insights and global capabilities to develop the most promising drug candidates across a range of therapeutic categories. The Company will utilize a "hub-and-spoke" model to create and advance specialized subsidiary companies which maintain operational focus and agility. By focusing each spoke on a specific asset or therapeutic area, the Company can optimally manage risk and create value through potential partnering transactions.

The company also announced the pending acquisition of VIS-101, a novel bifunctional biologic targeting VEGF-A and ANG2. The pending acquisition will be made by a newly formed subsidiary, Visara and is expected to be completed later this month. In addition, the company reaffirmed its previously announced givastomig investment plans as part of its new strategy. Kyler Lei has been named CFO of I-Mab. "We believe we are entering a new era of rapid growth in the global biotech economy, driven by greater innovation capability in China and Asia and a resurgence of investment in high growth international markets across Asia. With our new business model, we are uniquely positioned to strategically create significant value for patients and investors," said Mr. Fu Wei, Executive Chairman of I-Mab. "Through the strategic insight of our expanded Board, backing by CBC Group, Asia's largest dedicated healthcare asset management firm, and our dual listing strategy, I-Mab is ideally placed to partner with leading global innovators to identify and accelerate high-value assets. The proposed dual listing on both NASDAQ and HKEX is a key element of our global growth strategy. This move will enable us to broaden and diversify our investor base, and enhance trading liquidity and access to capital, while strengthening our presence with key stakeholders in the rapidly growing Asian market. 2025 has been a time of significant progress for I-Mab. Presentation of compelling Phase 1b givastomig combination data reinforced our confidence in its potential to be a best-in-class Claudin 18.2-directed therapy for gastric cancer and drove our plans to initiate a global randomized Phase 2 study, expected to begin in Q1 2026. In addition, the Company recently secured additional capital, and has attracted seasoned biotech executives to the Board of Directors and Scientific Advisory Board," said Sean Fu CEO of I-Mab. "With the strong foundation from our work on givastomig, and excellent progress this year, we are optimistic about moving forward with our new strategy. Our new global platform allows us to uphold our commitment to value creation by realizing the full potential of innovative medicines and improving the lives of patients."

I-Mab announced its new business model, focused on its global capabilities built to accelerate access to medicines and to enable broad strategic growth. The company announced its intention to pursue a Hong Kong IPO through dual listing on Nasdaq and Hong Kong Stock Exchange. The company intends to operate under the new name of NovaBridge Biosciences.